This site is intended only for healthcare professionals resident in Egypt
Menu
Close
Menu
Close
![]() |
of responses were rated as excellent* (157 of 172) indicating that prophylaxis treatment completely prevented spontaneous musculoskeletal bleeding2 |
*Rated by the investigator at 3-month intervals on a 3-point scale: excellent (prophylaxis treatment completely prevented spontaneous musculoskeletal bleeding, no change in dosing regimen necessary) effective (adequately prevented spontaneous musculoskeletal bleeding episodes as demonstrated by a lower than expected incidence of spontaneous musculoskeletal bleeding episodes); or inadequate (inadequate prevention of bleeding requiring a change in dosing regimen).2
†The response to secondary prophylaxis was assessed once every 3 months by the investigator using a 3-point scale: excellent (no spontaneous bleeding of any kind, no change in dosing regimen necessary); effective (no spontaneous musculoskeletal bleeding, no change in dosing regimen necessary) or inadequate (inadequate prevention of bleeding requiring a change in dosing regimen).3
FIX: factor IX; PTP: previously treated patient; PUP: previously untreated patient.
References:
Approval No. : BV0098A2259/032022
Invalidation Date: 17/02/2025 |
![]() |
Adverse events should be reported. Adverse events can be reported to [email protected]
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
The product information provided in this site is intended only for Healthcare Professionals of Egypt. The products discussed herein may have different product labeling in different countries.
Copyright © 2023 Pfizer biopharmaceutical LLC. All rights reserved.
These pages are not intended for patients or members of the general public. This portal contains healthcare promotional content.
If you select ""No"", you will be redirected to Pfizer.com, the global Pfoizer websitee.
I confirm that i am a healthcare professional resident in Egypt.